BioRestorative Therapies
BRTX
14 hedge funds and large institutions have $1.02M invested in BioRestorative Therapies in 2023 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 0 increasing their positions, 3 reducing their positions, and 3 closing their positions.
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
8% more funds holding
Funds holding: 13 → 14 (+1)
1.01% less ownership
Funds ownership: 8.93% → 7.93% (-1%)
23% less capital inflows, than outflows
Capital inflows: $209K | Capital outflows: $272K
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Advisers
New York
|
+$89.3K |
| 2 |
State Street
Boston,
Massachusetts
|
+$62.8K |
| 3 |
Two Sigma Investments
New York
|
+$52.2K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$4.91K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Ayrton Capital
Westport,
Connecticut
|
-$114K |
| 2 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
-$77K |
| 3 |
Boothbay Fund Management
New York
|
-$33.8K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$27.9K |
| 5 |
SG
StoneX Group
New York
|
-$10.4K |
BRTX Hedge Fund Activity: Q1 2023 in Review
14 of the 6,287 institutional investors tracked by Wall St. Rank reported a position in BioRestorative Therapies (BRTX) for Q1 2023, worth a combined $1.02M — up 13% from $900K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new BRTX positions and 3 closed out — a net gain of 1 holder — while 0 added to existing stakes and 3 trimmed.
The largest buyer was Two Sigma Advisers, opening a new position worth an estimated $89.3K. The largest seller was Ayrton Capital, exiting entirely with an estimated $114K sold.
- 14 institutional investors held BioRestorative Therapies (BRTX) as of Q1 2023, up from 13 in Q4 2022.
- Funds reported $1.02M of BioRestorative Therapies stock for Q1 2023, up 13% quarter-over-quarter.
- 4 funds opened new BioRestorative Therapies positions in Q1 2023 and 3 closed out, a net change of +1 holder.
- The largest BioRestorative Therapies buyer in Q1 2023 was Two Sigma Advisers, an estimated $89.3K added.
- The largest BioRestorative Therapies seller in Q1 2023 was Ayrton Capital, an estimated $114K sold.
Based on aggregated 13F filings for Q1 2023.